Ara
Toplam kayıt 837, listelenen: 831-837
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...
Chronobiological efficacy of combined therapy of pelargonium sidoides and melatonin in acute and persistent cases of COVID-19: A hypothetical approach
(Springer, 2023)
Since the outbreak of the first SARS-CoV-2 epidemic in China, pharmacists have rapidly engaged and developed strategies for pharmaceutical care and supply. According to the guidelines of the International Pharmaceutical ...
Turkish translation and crosscultural validity of WHOQoL-HIV Bref Tool
(Wiley, 2023)
...